Osimertinib—first or second line for epidermal growth factor (EGFR) mutation-positive non-small cell lung cancer?

Eitemau Tebyg

• First-line osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer
  gan: Jeong, Byeong-Ho, et al.
  Cyhoeddwyd: (2018)
• Management of non-small cell lung cancer harboring epidermal growth factor receptor mutations in the era of first-line osimertinib
  gan: Hakozaki, Taiki, et al.
  Cyhoeddwyd: (2019)
• First‐line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non‐squamous non‐small cell lung cancer
  gan: Greenhalgh, Janette, et al.
  Cyhoeddwyd: (2021)
• Osimertinib in untreated epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer
  gan: Gregorc, Vanesa, et al.
  Cyhoeddwyd: (2018)
• Moving osimertinib to first-line: the right “strategy” in the chessboard of epidermal growth factor receptor-mutated non-small cell lung cancer?
  gan: Passiglia, Francesco, et al.
  Cyhoeddwyd: (2018)